These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28111042)

  • 81. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
    Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
    Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy.
    Giuroiu I; Weber J
    Cancer J; 2017; 23(1):23-31. PubMed ID: 28114251
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Novel immunotherapy combinations for genitourinary cancers.
    Al Harthy M; Redman J; Madan RA
    Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The cancer associated antigen test as an index to failure of complete removal of urological cancers.
    Wechsler M; Gerfo PL; Feminella J; Lattimer JK
    J Urol; 1973 Apr; 109(4):699-701. PubMed ID: 4735168
    [No Abstract]   [Full Text] [Related]  

  • 85. Immunotherapy in genitourinary malignancies.
    Wattenberg MM; Fong L; Madan RA; Gulley JL
    Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].
    Ladoire S; Derangère V; Arnould L; Thibaudin M; Coudert B; Lorgis V; Desmoulins I; Chaix M; Fumoleau P; Ghiringhelli F
    Ann Pathol; 2017 Feb; 37(1):133-141. PubMed ID: 28159406
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Immunotherapy for osteosarcoma: Where do we go from here?
    Wedekind MF; Wagner LM; Cripe TP
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Genitourinary cancer.
    Hudes GR; Grana G; Deshields MS; Ozols RF
    Cancer Chemother Biol Response Modif; 1992; 13():508-40. PubMed ID: 1389919
    [No Abstract]   [Full Text] [Related]  

  • 90. Cutaneous response to dinitrochlorobenzene in patients with genito-urinary cancers.
    Duclos H; Schwarzenberg L; Duclos SH; Hugues H; Kuss R
    Biomedicine; 1977 Jan; 27(1):43-7. PubMed ID: 856314
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Strategies around PD-L1 testing in France].
    Penault-Llorca F
    Ann Pathol; 2017 Feb; 37(1):3-4. PubMed ID: 28108043
    [No Abstract]   [Full Text] [Related]  

  • 92. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

  • 93. Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.
    Yu SS; Ballas LK; Skinner EC; Dorff TB; Sadeghi S; Quinn DI
    Clin Adv Hematol Oncol; 2017 Jul; 15(7):543-551. PubMed ID: 28749918
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Genitourinary cancer.
    Ozols RF; Yagoda A
    Cancer Chemother Biol Response Modif; 1990; 11():602-29. PubMed ID: 2171615
    [No Abstract]   [Full Text] [Related]  

  • 95. [Urological cancer: treatment strategies].
    Srougi M; de Góes GM
    AMB Rev Assoc Med Bras; 1983; 29(11-12):199-209. PubMed ID: 6369432
    [No Abstract]   [Full Text] [Related]  

  • 96. [Not Available].
    Vano YA; Simonaggio A; Thibault C; Oudard S
    Bull Cancer; 2018 Dec; 105 Suppl 1():S24-S34. PubMed ID: 30595195
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Treatment of early urogenital cancer].
    Rinsho K; Koiso K
    Gan No Rinsho; 1984 May; 30(6 Suppl):653-8. PubMed ID: 6748240
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
    Sundararajan S; Vogelzang NJ
    Future Oncol; 2015; 11(16):2299-306. PubMed ID: 26260808
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Genitourinary cancer.
    Ozols RF; Yagoda A
    Cancer Chemother Biol Response Modif; 1987; 9():280-302. PubMed ID: 2856337
    [No Abstract]   [Full Text] [Related]  

  • 100. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
    Falchi L
    Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.